Home
|
Inbox
|
Search
|
Speaker
Vallerie V. McLaughlin
MD
Director of Pulmonary Hypertension Program, University of Michigan;University of Michigan;University of Michigan Medical Center
Session(s)
- Baseline and Demographic Data on the First 250 Patients from SPHERE (Uptravi® [SelexiPag]:...
Tuesday, May 22 11:15 AM - 1:00 PM - Patient Characteristics and Treatment Patterns in the Largest Real-World Cohort of Pulmona...
Tuesday, May 22 11:15 AM - 1:00 PM - Transitions from Inhaled, Intravenous, Subcutaneous, or Oral Prostacyclins to Selexipag: I...
Tuesday, May 22 11:15 AM - 1:00 PM - Association of NT-proBNP and Long-Term Outcome in Pulmonary Arterial Hypertension (PAH): I...
Wednesday, May 23 1:30 PM - 3:30 PM - Ralinepag Plasma Levels Correlate with Improvements in Functional and Hemodynamic Paramete...
Wednesday, May 23 1:30 PM - 3:30 PM - Real-World Dosing and Titration of Selexipag in Patients with Pulmonary Arterial Hypertens...
Wednesday, May 23 1:30 PM - 3:30 PM
|
Home
|
Inbox
|
Search
|